<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FAA51396-5490-4A7E-AD18-F5FC3DE42172"><gtr:id>FAA51396-5490-4A7E-AD18-F5FC3DE42172</gtr:id><gtr:firstName>Stephanie</gtr:firstName><gtr:surname>Cragg</gtr:surname><gtr:orcidId>0000-0001-9677-2256</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D2A01CA7-6EF4-418B-B4E8-DE06B7AC2E71"><gtr:id>D2A01CA7-6EF4-418B-B4E8-DE06B7AC2E71</gtr:id><gtr:firstName>Katie</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Jennings</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ004324%2F1"><gtr:id>345A9A30-0FBD-4E9E-85A2-AC32336AAB71</gtr:id><gtr:title>Defining the striatal dopamine signals that enable movement: a high resolution spatiotemporal characterisation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J004324/1</gtr:grantReference><gtr:abstractText>Context of the research: We know that a chemical transmitter in the brain called dopamine is critical for our movements. For instance, loss of dopamine from the brain area called the striatum causes the movement problems seen in Parkinson's disease, and too much dopamine is thought to cause excessive, or compulsive behaviours. However, we still do not fully understand how dopamine is important. If we are to understand how best to treat dopamine disorders, we need to understand better how dopamine controls movement. Release of dopamine in the striatum occurs in two modes; either as low level 'tonic' release, or as intermittent intense surges, named 'phasic' release. Phasic dopamine release is known to be critical for motivating our behaviours e.g. making us seek rewards, and is thought to be hijacked in addiction disorders. New evidence now suggests that phasic dopamine release may have wider roles too, in controlling more types of movement that are unrelated to rewards. However, this suggestion has not yet been proven. Experiments to date have investigated the role of phasic dopamine release only in parts of the striatum known to be involved in processing motivation-related information (such as rewards) rather than in the 'motor' striatum, which is important for selecting everyday movement and which, importantly, loses dopamine in PD. Therefore, we propose to address the question - is phasic dopamine in the motor striatum important for movement? Excitingly, the technology has now been fully developed to make this a highly timely question. We will also address closely related questions about how other key chemicals in the striatum might regulate these phasic dopamine signals. 
Aims and objectives of the research: The broad aim of this research is to determine whether phasic dopamine release in the brain's striatum is important for many types of movement, not just those related to rewards. We will address this through two specific aims. 
There is general agreement among scientists that the motor striatum might be particularly important for carrying out our learned movements which have become automatic habits (e.g. standing and walking). Importantly, these types of habitual movements are often impaired in PD. Therefore in Aim 1, we will focus on - is phasic dopamine release in the motor-associated striatum important for habitual behaviour? We will assess dopamine release seen in motor striatum during a range of behaviours involving reward-seeking movement, non-reward-seeking movement and learned habitual movements so that we can identify the role of phasic dopamine in different key types of behaviours. We will also compare the phasic dopamine signals seen in the motor striatum to those seen in the motivation-associated parts of the striatum, to be able to understand more about the regulation of different kinds of movements.
Another brain transmitter, acetylcholine, is also known to be important for movement, especially reward-seeking and habits, and our previous work has shown that acetylcholine regulates phasic dopamine release in brain slices. However, this control has not yet been confirmed in behaving animals. Thus, in Aim 2, we will address - is phasic dopamine release governed by acetylcholine? 
Potential applications and benefits of the research: Through this work, we can begin to build a more complete picture of how dopamine really participates in regulating our movement. In turn, we will shed light on fundamental mechanisms of normal brain function that might be disrupted, and then targeted for therapeutic benefit, in disorders of dopamine neuron function, including PD and addiction disorders. Also, the technical infrastructure that we will establish will be cutting-edge and an excellent investment for future studies to investigate dopamine function further e.g. in disease. Therefore, whatever the outcome, our work will provide a fundamental advance in knowledge and be of direct benefit to future work.</gtr:abstractText><gtr:technicalSummary>Mesostriatal dopamine (DA) neurons switch their activity between low, 'tonic' firing frequencies and intermittent, 'phasic' bursts of high frequency action potentials. The intermittent, phasic release of DA within the limbic-associated ventral striatum is important for signalling reward predictions and reinforcement learning. Phasic DA release here seems particularly important for initiating reward-seeking movement. The motor-associated dorsal striatum suffers the most profound DA loss in the movement disorder Parkinson's disease (PD), but it is poorly understood whether phasic DA release here participates in behaviours, whether these be reward-seeking, or other reward-unrelated movements that are affected in PD such as habitual movement. 
We shall address the importance of phasic DA release in vivo in (i) 'motor' striatum for voluntary movement and in (ii) 'limbic' striatum for movements unrelated to reward. We will use fast-scan cyclic voltammetry to identify DA release in motor versus limbic striatum during movements which depend differently on these regions and on reward. DA will be detected simultaneously from both regions during reward-seeking, habit performance and unrewarded locomotor movement in mice. We will also explore how phasic DA release is regulated presynaptically by interactions with striatal ACh networks in vivo, by using ligands for ACh receptors that are known to modulate phasic-like DA release in vitro. These timely experiments should allow us to define the roles of striatal phasic DA in movement and of striatal ACh in influencing discrete DA signals in vivo. This work should offer unprecedented insights into how dysfunction of DA signals could underlie disorders such as PD and addiction. A better understanding of discrete DA signalling during movement could in turn be highly influential in guiding the design of improved DA-based therapies e.g. discrete strategies to boost phasic versus tonic DA levels.</gtr:technicalSummary><gtr:potentialImpactText>In addition to the immediate impact on work by academic researchers, as outlined in 'Academic Beneficiaries', in the longer term this work could have impact on the quality of life of Parkinson's disease sufferers and their carers. 
This is the first study to our knowledge to explore a potential role for phasic DA release in controlling movements relevant to Parkinson's disease and in the appropriate brain region that loses dopamine during this debilitating disease. Thus, our findings should stimulate a new line of investigation in the field of Parkinson's research. 
Our proposed work should shed light on whether phasic DA release is important in voluntary movement, and thus whether it and all of its potential regulatory mechanisms could be useful therapeutic targets in DA disorders. Therefore we expect that our findings will be critical in advancing the search for more efficient therapies.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-14</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>368338</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration PEM Phillips 2012-2015</gtr:description><gtr:id>6A1B1F77-FBE9-4B69-AD61-79F0429D5FE3</gtr:id><gtr:impact>Grant MR/J004324/1</gtr:impact><gtr:partnerContribution>Advice on use of probes</gtr:partnerContribution><gtr:piContribution>Studying function of DA circuits in vivo</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Speaker and Opening of fundraising walk for Parkinson's UK, Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8C91A40A-216E-4458-95CE-711B660226EF</gtr:id><gtr:impact>Speaker and Opening of fundraising walk for Parkinson's UK, Oxford</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>https://www.parkinsons.org.uk/content/walk-parkinsons</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's group talk Hereford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E633185B-8A78-4BF2-BAC9-C9A5F2296E68</gtr:id><gtr:impact>Share knowledge, stimulate interest

After the talk, audience asked to visit lab</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuroscience exhibition in the Oxford museum of Science  March 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C32B9CFB-AA4B-473B-AF18-4EF36FD27384</gtr:id><gtr:impact>Neuroscience exhibition in the Oxford museum of Science March 2014


Unknown</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Discuss Parkinson's research with individual fundraisers (DB, EL, SB)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>851D36A5-1B01-4B19-92C1-FB042887CD52</gtr:id><gtr:impact>Engagement with small groups of charitable donors to promote fundraising into Parkinson's research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2009,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edinburgh International Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B055A96-6FEE-43F3-9DAA-2308BCC400A0</gtr:id><gtr:impact>Talk sparked questions and debate

N/A</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.co.uk/mediaLibrary/other/english/6285.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Innovations article 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2336F480-F89D-48FA-B292-7BE48B76D516</gtr:id><gtr:impact>Publication in internationally reaching magazine.
results not yet clear.

Not yet clear</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.internationalinnovation.com/hope-for-dopamine-disorders/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Clarendon Fund</gtr:department><gtr:description>DPhil Studentship BR</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>61428892-4AF1-44BF-BC92-FE8C8D311916</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG Studentship 2013</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>ED47B686-AE29-4A4C-A548-5B160EA02FED</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>297158</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Parkinson's UK Project Grant 2015</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:fundingRef>G1504</gtr:fundingRef><gtr:id>EFF6C314-C60E-4DBB-8482-F8E65C229884</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79546</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC-DTG Studentship 2014</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BE879D5A-604D-4DAC-9771-F71C6DB060FF</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24450</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC In Vivo Strategic Skill Award 2013</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9721822F-A3FE-4402-A084-722736AE0AD2</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Monument Trust Discovery Award Renewal 2015</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Parkinson's UK (Parkinson's Disease Society)</gtr:fundingOrg><gtr:fundingRef>J-1403</gtr:fundingRef><gtr:id>8F9F93DA-2360-4858-A25F-76B88E8DE63E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34AC3BA9-AC85-45B6-84D7-2A4CFCF0B281"><gtr:id>34AC3BA9-AC85-45B6-84D7-2A4CFCF0B281</gtr:id><gtr:title>Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d6668951c862e0eb1aa2f5013bccfb1"><gtr:id>4d6668951c862e0eb1aa2f5013bccfb1</gtr:id><gtr:otherNames>Kosillo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F6B3C8B-99BD-4FE6-BBB5-43F453877FE6"><gtr:id>3F6B3C8B-99BD-4FE6-BBB5-43F453877FE6</gtr:id><gtr:title>Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a4910b85ad214d16d15c09bdceae7a35"><gtr:id>a4910b85ad214d16d15c09bdceae7a35</gtr:id><gtr:otherNames>Janezic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E88743B-57AA-4EC9-BC2A-09EE634F6559"><gtr:id>2E88743B-57AA-4EC9-BC2A-09EE634F6559</gtr:id><gtr:title>A comparison of the subsecond dynamics of neurotransmission of dopamine and serotonin.</gtr:title><gtr:parentPublicationTitle>ACS chemical neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/281e8ccd9dac9521ceadfbc748fd53c9"><gtr:id>281e8ccd9dac9521ceadfbc748fd53c9</gtr:id><gtr:otherNames>Jennings KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1948-7193</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F432F0D-EB42-4684-B59A-3B1E0A8329F2"><gtr:id>1F432F0D-EB42-4684-B59A-3B1E0A8329F2</gtr:id><gtr:title>Striatal dopamine neurotransmission: regulation of release and uptake.</gtr:title><gtr:parentPublicationTitle>Basal ganglia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b6bd6a9f7ec85a661959fd1535e37bc"><gtr:id>5b6bd6a9f7ec85a661959fd1535e37bc</gtr:id><gtr:otherNames>Sulzer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2210-5336</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BDE3E215-2607-44B9-B0BF-8014B1FC7330"><gtr:id>BDE3E215-2607-44B9-B0BF-8014B1FC7330</gtr:id><gtr:title>Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P a-synuclein BAC transgenic mouse.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b87408ab4631e28cdf76393ba4d8012b"><gtr:id>b87408ab4631e28cdf76393ba4d8012b</gtr:id><gtr:otherNames>Taylor TN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1CD0217-5EE2-4B72-A7CD-27540148CFEE"><gtr:id>F1CD0217-5EE2-4B72-A7CD-27540148CFEE</gtr:id><gtr:title>Transcription factors FOXA1 and FOXA2 maintain dopaminergic neuronal properties and control feeding behavior in adult mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ac84e5d9bf96fbc5e0260019152f0e5"><gtr:id>9ac84e5d9bf96fbc5e0260019152f0e5</gtr:id><gtr:otherNames>Prister? A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D7CECA2-DC90-4A09-A037-ABDD2F8D6677"><gtr:id>0D7CECA2-DC90-4A09-A037-ABDD2F8D6677</gtr:id><gtr:title>Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e595a79b0bb73260843d5fc572664497"><gtr:id>e595a79b0bb73260843d5fc572664497</gtr:id><gtr:otherNames>Brimblecombe KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B11CEB7F-DAA7-4D38-9A0C-71D4A336E5CA"><gtr:id>B11CEB7F-DAA7-4D38-9A0C-71D4A336E5CA</gtr:id><gtr:title>Representation of spontaneous movement by dopaminergic neurons is cell-type selective and disrupted in parkinsonism.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0630e02feac27cd5406058fc71abc53a"><gtr:id>0630e02feac27cd5406058fc71abc53a</gtr:id><gtr:otherNames>Dodson PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF35E1F6-E586-4C5C-B6F8-DC0C4B1A66CF"><gtr:id>FF35E1F6-E586-4C5C-B6F8-DC0C4B1A66CF</gtr:id><gtr:title>The impact of a parkinsonian lesion on dynamic striatal dopamine transmission depends on nicotinic receptor activation.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/281e8ccd9dac9521ceadfbc748fd53c9"><gtr:id>281e8ccd9dac9521ceadfbc748fd53c9</gtr:id><gtr:otherNames>Jennings KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J004324/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>